NEW YORK (GenomeWeb News) – Evotec today said that it has forged an alliance with the Harvard Stem Cell Institute to identify compounds that can prevent or slow down the loss of motor neurons, a characteristic of amyotrophic lateral sclerosis.

The collaboration, dubbed CureMN, or CureMotorNeuron, will leverage Evotec's drug discovery infrastructure and expertise in identifying compounds with therapeutic value, as well as human motor neuron assays based on ALS patient-derived induced pluripotent stem cells developed by HSCI principal faculty members Lee Rubin and Kevin Eggan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.